ABO and Schnyder corneal dystrophy: Seventy‐one percent of non‐sickle cell treatment centres (SCTCs) and 20% of non‐thalassemia treatment centres follow NHLBI and TIF recommendations to perform a red blood cell phenotype beyond ABO/Rh(D) and provide Rh and Kell prophylactically matched units for SCD and thalassemia patients, respectively.